Skip to content

因文蒂瓦

US · IVA #3421 按市值排名 上市于 2020
2.94 -0.17 -5.47%
实时 - 追踪5344个代码 - 心跳于324秒前 · 2026-10-16 19:53

估值 各估值倍数与自身5年区间的对比

市净率 12.02 高于历史水平 第100百分位
5年平均 -15.03 · 在Biotechnology中排名第451/513
市盈率 -5.63 低于历史水平 第14百分位
5年平均 -2.82 · 前瞻 -3.82
市销率 14,496.33 高于历史水平 第100百分位
5年平均 230.11 · 前瞻 250.30 · 在Biotechnology中排名第376/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
因文蒂瓦 (IVA) 694.53M -4.91 10.50 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值5.16 经济护城河Narrow 不确定性Very High

当前股价低于晨星合理价值估算75.4%。

合理价值

Inventiva SA is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 35% discount to our quantitative fair value estimate of $5.16 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 0.8 lies in the bottom 20% globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, for example, falls in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

经济护城河

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:53:14 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

因文蒂瓦 讨论区 0 条评论

发表评论